Europe — EMA
Omvoh (Mirikizumab)
Mirikizumab, the active ingredient in Omvoh, is a monoclonal antibody presented as a strength/form for intravenous use. It modulates immune activity and is indicated for certain inflammatory bowel diseases in adult…
Request sourcing
What is Mirikizumab?
Mirikizumab, the active ingredient in Omvoh, is a monoclonal antibody presented as a strength/form for intravenous use. It modulates immune activity and is indicated for certain inflammatory bowel diseases in adult patients. GNH USA supplies Omvoh as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals and specialty clinics worldwide.
GNH USA supplies Omvoh as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals and specialty clinics worldwide.
What is Mirikizumab used for?
Omvoh is a targeted immunomodulator used in the management of chronic inflammatory conditions affecting the gastrointestinal tract.
- Ulcerative colitis: reduces signs and symptoms, helping achieve clinical remission. - Crohn's disease: decreases intestinal inflammation and may induce mucosal healing. - Pouchitis after ileal pouch‑anal anastomosis: improves pouch inflammation and patient quality of life.
What are the side effects of Mirikizumab?
Common Side Effects: - Injection site reactions - Upper ... ... ... ... ... ... ... ... … ... … … ... … … … … … … … … … … - … … … … ... ... … … … ... … … … … … … … … … … … …
Serious or Rare ... … … ... ... … ... … … … … … …\
